NKF KDOQI GUIDELINES Executive Summaries | Anemia | Hemodialysis | Peritoneal Dialysis | Vascular Access | Nutrition | CKD 2002 | Dyslipidemias | Bone Metabolism | Hypertension and Antihypertensive Agents | Cardiovascular Disease in Dialysis Patients | History of KDOQI | Pediatric Bone | Anemia 2006 | Updates 2006 | Diabetes and Chronic Kidney Disease

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease

REFERENCES

1. Dirks JH, de Zeeuw D, Agarwal SK, et al: Prevention of chronic kidney and vascular disease: Toward global health equity—The Bellagio 2004 Declaration. Kidney Int Suppl 98:S1-S6, 2005

2. Lysaght MJ: Maintenance dialysis population dynamics: Current trends and long-term implications. J Am Soc Nephrol 13:S37-S40, 2002 (suppl 1)

3. National Kidney Foundation: KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis 39:S1-266, 2002 (suppl 1)

4. US Renal Data System: USRDS 2004 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2004

5. National Kidney Foundation: KDOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 43:S1-S290, 2004 (suppl 1)

6. National Kidney Foundation: KDOQI Clinical Practice Guidelines for Management of Dyslipidemias in Patients With Kidney Disease. Am J Kidney Dis 41:S1-S91, 2003 (suppl 3)

7. National Kidney Foundation:KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42:S1-S201, 2003 (suppl 3)

8. National Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47:S1-S145, 2006 (suppl 3)

9. National Kidney Foundation: KDOQI Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. Am J Kidney Dis 35:S1-S140, 2000 (suppl 2)

10. National Kidney Foundation:KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis 45:S1-S153, 2005 (suppl 3)

11. Knowler WC, Bennett PH, Bottazzo GF, Doniach D: Islet cell antibodies and diabetes mellitus in Pima Indians. Diabetologia 17:161-164, 1979

12. West KM: Diabetes in American Indians, in Levine R, Luft R (eds): Advances in Metabolic Disorders, vol 9. New York, NY, Academic, 1978, pp 29-47

13. Zimmet P: Globalization, coca-colonization and the chronic disease epidemic: Can the doomsday scenario be averted? J Intern Med 247:301-310, 2000

14. Engelgau MM, Geiss LS, Saaddine JB, et al: The evolving diabetes burden in the United States. Ann Intern Med 140:945-950, 2004

15. Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner SM, Stern MP: Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: Results from the San Antonio Heart Study. Arch Intern Med 159:1450-1456, 1999

16. Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. JAMA 281:1291-1297, 1999

17. Gale EA: The rise of childhood type 1 diabetes in the 20th century. Diabetes 51:3353-3361, 2002

18. Boyle JP, Honeycutt AA, Narayan KM, et al: Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the U.S. Diabetes Care 24:1936-1940, 2001

19. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053, 2004

20. Colagiuri S, Borch-Johnsen K, Glumer C, Vistisen D: There really is an epidemic of type 2 diabetes. Diabetologia 48:1459-1463, 2005

21. US Renal Data System: USRDS 2005 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2005

22. Motala AA, Pirie FJ, Gouws E, Amod A, Omar MA: Microvascular complications in South African patients with long-duration diabetes mellitus. S Afr Med J 91:987-992, 2001

23. Wanjohi FW, Otieno FC, Ogola EN, Amayo EO: Nephropathy in patients with recently diagnosed type 2 diabetes mellitus in black Africans. East Afr Med J 79:399-404, 2002

24. Ramachandran A, Snehalatha C, Latha E, Vijay V, Viswanathan M: Rising prevalence of NIDDM in an urban population in India. Diabetologia 40:232-237, 1997

25. Simmons D, Schaumkel J, Cecil A, Scott DJ, Kenealy T: High impact of nephropathy on five-year mortality rates among patients with type 2 diabetes mellitus from a multi-ethnic population in New Zealand. Diabet Med 16:926-931, 1999

26. Park JY, Kim HK, Chung YE, Kim SW, Hong SK, Lee KU: Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes. Diabetes Care 21:530-534, 1998

27. Wu AY, Kong NC, de Leon FA, et al: An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: The MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 48:17-26, 2005

28. Sobngwi E, Mauvais-Jarvis F, Vexiau P, Mbanya JC, Gautier JF: Diabetes in Africans. Part 1: Epidemiology and clinical specificities. Diabetes Metab 27:628-634, 2001

29. Earle KK, Porter KA, Ostberg J, Yudkin JS: Variation in the progression of diabetic nephropathy according to racial origin. Nephrol Dial Transplant 16:286-290, 2001

30. Koppiker N, Feehally J, Raymond N, Abrams KR, Burden AC: Rate of decline in renal function in Indo-Asians and whites with diabetic nephropathy. Diabet Med 15:60-65, 1998

31. Chandie Shaw PK, van Es LA, Paul LC, Rosendaal FR, Souverijn JH, Vandenbroucke JP: Renal disease in relatives of Indo-Asian type 2 diabetic patients with end-stage diabetic nephropathy. Diabetologia 46:618-624, 2003

32. Chandie Shaw PK, Vandenbroucke JP, Tjandra YI, et al: Increased end-stage diabetic nephropathy in Indo-Asian immigrants living in The Netherlands. Diabetologia 45:337-341, 2002

33. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 414:782-787, 2001

34. Standards of medical care in diabetes—2006. Diabetes Care 29:S4-S42, 2006 (suppl 1)

35. Molitch ME, DeFronzo RA, Franz MJ, et al: Nephropathy in diabetes. Diabetes Care 27:S79-S83, 2004 (suppl 1)

36. Feldt-Rasmussen B: Microalbuminuria and clinical nephropathy in type 1 (insulin-dependent) diabetes mellitus: Pathophysiological mechanisms and intervention studies. Dan Med Bull 36:405-415, 1989

37. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998

38. Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO: Prevention Conference VI: Diabetes and Cardiovascular Disease: Executive summary: Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 105:2231-2239, 2002

39. Sarnak MJ, Levey AS, Schoolwerth AC, et al: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154-2169, 2003

40. Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157:1413-1418, 1997

41. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225-232, 2003

42. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 27:2033-2039, 1996

43. Valmadrid CT, Klein R, Moss SE, Klein BE: The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160:1093-1100, 2000

44. Foley RN, Murray AM, Li S, et al: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16:489-495, 2005

45. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003

46. Gaede P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet 353:617-622, 1999

47. Carey VJ, Walters EE, Colditz GA, et al: Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol 145:614-619, 1997

48. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC: Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 17:961-969, 1994

49. Kaye SA, Folsom AR, Sprafka JM, Prineas RJ, Wallace RB: Increased incidence of diabetes mellitus in relation to abdominal adiposity in older women. J Clin Epidemiol 44:329-334, 1991

50. Lundgren H, Bengtsson C, Blohme G, Lapidus L, Sjostrom L: Adiposity and adipose tissue distribution in relation to incidence of diabetes in women: Results from a prospective population study in Gothenburg, Sweden. Int J Obes 13:413-423, 1989

51. Ohlson LO, Larsson B, Svardsudd K, et al: The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 Years of follow-up of the participants in the study of men born in 1913. Diabetes 34:1055-1058, 1985

52. Sargeant LA, Bennett FI, Forrester TE, Cooper RS, Wilks RJ: Predicting incident diabetes in Jamaica: The role of anthropometry. Obes Res 10:792-798, 2002

53. Warne DK, Charles MA, Hanson RL, et al: Comparison of body size measurements as predictors of NIDDM in Pima Indians. Diabetes Care 18:435-439, 1995

54. Wei M, Gaskill SP, Haffner SM, Stern MP: Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans—A 7-year prospective study. Obes Res 5:16-23, 1997

55. Tulloch-Reid MK, Williams DE, Looker HC, Hanson RL, Knowler WC: Do measures of body fat distribution provide information on the risk of type 2 diabetes in addition to measures of general obesity? Comparison of anthropometric predictors of type 2 diabetes in Pima Indians. Diabetes Care 26:2556-2561, 2003

56. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U: Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 278:F817-F822, 2000

57. Ribstein J, du Cailar G, Mimran A: Combined renal effects of overweight and hypertension. Hypertension 26:610-615, 1995

58. Folsom AR, Kushi LH, Hong CP: Physical activity and incident diabetes mellitus in postmenopausal women. Am J Public Health 90:134-138, 2000

59. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr: Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 325:147-152, 1991

60. Kriska AM, Saremi A, Hanson RL, et al: Physical activity, obesity, and the incidence of type 2 diabetes in a high-risk population. Am J Epidemiol 158:669-675, 2003

61. Manson JE, Nathan DM, Krolewski AS, Stampfer MJ, Willett WC, Hennekens CH: A prospective study of exercise and incidence of diabetes among US male physicians. JAMA 268:63-67, 1992

62. Manson JE, Rimm EB, Stampfer MJ, et al: Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 338:774-778, 1991

63. Knowler WC, Barrett-Connor E, Fowler SE, et al: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002

64. Pan XR, Li GW, Hu YH, et al: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997

65. Tuomilehto J, Lindstrom J, Eriksson JG, et al: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001

66. Molitch ME, Fujimoto W, Hamman RF, Knowler WC: The diabetes prevention program and its global implications. J Am Soc Nephrol 14:S103-S107, 2003 (suppl 2)

67. Ramachandran A, Snehalatha C, Vinitha R, et al: Prevalence of overweight in urban Indian adolescent school children. Diabetes Res Clin Pract 57:185-190, 2002

68. Pazmino PA, Pazmino AK: Diabetic renal failure in Texas: Influence of ethnicity and household income. Tex Med 99:57-65, 2003

69. Brancati FL, Whelton PK, Kuller LH, Klag MJ: Diabetes mellitus, race, and socioeconomic status. A population-based study. Ann Epidemiol 6:67-73, 1996

70. Hazuda HP, Haffner SM, Stern MP, Eifler CW: Effects of acculturation and socioeconomic status on obesity and diabetes in Mexican Americans. The San Antonio Heart Study. Am J Epidemiol 128:1289-1301, 1988

71. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M: Type 2 diabetes in the young: The evolving epidemic: The International Diabetes Federation Consensus Workshop. Diabetes Care 27:1798-1811, 2004

72. Singh R, Shaw J, Zimmet P: Epidemiology of childhood type 2 diabetes in the developing world. Pediatr Diabetes 5:154-168, 2004

73. Acton KJ, Burrows NR, Moore K, Querec L, Geiss LS, Engelgau MM: Trends in diabetes prevalence among American Indian and Alaska native children, adolescents, and young adults. Am J Public Health 92:1485-1490, 2002

74. Kitagawa T, Owada M, Urakami T, Yamauchi K: Increased incidence of non-insulin dependent diabetes mellitus among Japanese schoolchildren correlates with an increased intake of animal protein and fat. Clin Pediatr (Phila) 37:111-115, 1998

75. Urakami T, Kubota S, Nitadori Y, Harada K, Owada M, Kitagawa T: Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. Diabetes Care 28:1876-1881, 2005

76. Dabelea D, Hanson RL, Bennett PH, Roumain J, Knowler WC, Pettitt DJ: Increasing prevalence of type II diabetes in American Indian children. Diabetologia 41:904-910, 1998

77. Pettitt DJ, Baird HR, Aleck KA, Bennett PH, Knowler WC: Excessive obesity in offspring of Pima Indian women with diabetes during pregnancy. N Engl J Med 308:242-245, 1983

78. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al: Type 2 diabetes among North American children and adolescents: An epidemiologic review and a public health perspective. J Pediatr 136:664-672, 2000

79. Krakoff J, Lindsay RS, Looker HC, Nelson RG, Hanson RL, Knowler WC: Incidence of retinopathy and nephropathy in youth-onset compared with adult-onset type 2 diabetes. Diabetes Care 26:76-81, 2003

80. Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG: Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 296:421-426, 2006

81. Lee ET, Keen H, Bennett PH, Fuller JH, Lu M: Follow-up of the WHO Multinational Study of Vascular Disease in Diabetes: General description and morbidity. Diabetologia 44:S3-S13, 2001 (suppl 2)

82. Lee ET, Lu M, Bennett PH, Keen H: Vascular disease in younger-onset diabetes: Comparison of European, Asian and American Indian cohorts of the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44:S78-S81, 2001 (suppl 2)

83. Uchigata Y: Long-term outcome of type 2 diabetes in adolescence, in Silink M, Kida K, Rosenbloom AL (eds): Type 2 Diabetes in Childhood and Adolescence: A Global Perspective. New York, NY, Dunitz, 2003, pp 187-210

84. Yokoyama H, Okudaira M, Otani T, et al: Existence of early-onset NIDDM Japanese demonstrating severe diabetic complications. Diabetes Care 20:844-847, 1997

85. Brown AF, Mangione CM, Saliba D, Sarkisian CA: Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 51:S265-S280, 2003 (suppl)

86. Pettitt DJ, Knowler WC: Diabetes and obesity in the Pima Indians: A crossgenerational vicious cycle. J Obes Weight Regul 7:61-65, 1988

87. Nelson RG, Morgenstern H, Bennett PH: Intrauterine diabetes exposure and the risk of renal disease in diabetic Pima Indians. Diabetes 47:1489-1493, 1998

88. Gregg EW, Beckles GL, Williamson DF, et al: Diabetes and physical disability among older U.S. adults. Diabetes Care 23:1272-1277, 2000

89. Volpato S, Blaum C, Resnick H, Ferrucci L, Fried LP, Guralnik JM: Comorbidities and impairments explaining the association between diabetes and lower extremity disability: The Women's Health and Aging Study. Diabetes Care 25:678-683, 2002

90. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102:520-526, 1984

91. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527-532, 1984

92. McKenna MT, Michaud CM, Murray CJ, Marks JS: Assessing the burden of disease in the United States using disability-adjusted life years. Am J Prev Med 28:415-423, 2005

93. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB: Mortality among diabetics in a national sample. Am J Epidemiol 128:389-401, 1988

94. Borch-Johnsen K, Andersen PK, Deckert T: The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28:590-596, 1985

95. Nelson RG, Pettitt DJ, Carraher MJ, Baird HR, Knowler WC: Effect of proteinuria on mortality in NIDDM. Diabetes 37:1499-1504, 1988

96. Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E: Proteinuria and mortality in diabetes: The WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med 12:149-155, 1995

97. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360:7-22, 2002

98. Colhoun HM, Betteridge DJ, Durrington PN, et al: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364:685-696, 2004

99. Tonelli M, Keech A, Shepherd J, et al: Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 16:3748-3754, 2005

100. Wanner C, Krane V, Marz W, et al: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-248, 2005

101. Wackers FJ, Young LH, Inzucchi SE, et al: Detection of silent myocardial ischemia in asymptomatic diabetic subjects: The DIAD study. Diabetes Care 27:1954-1961, 2004

102. Antman EM, Anbe DT, Armstrong PW, et al: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110:282-292, 2004

103. Pfeffer MA, McMurray JJ, Velazquez EJ, et al: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893-1906, 2003

104. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000

105. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000

106. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134:629-636, 2001

107. Tokmakova MP, Skali H, Kenchaiah S, et al: Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: The Survival And Ventricular Enlargement (SAVE) Study. Circulation 110:3667-3673, 2004

108. Bakris GL, Fonseca V, Katholi RE, et al: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA 292:2227-2236, 2004

109. Malmberg K, Ryden L, Efendic S, et al: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year. J Am Coll Cardiol 26:57-65, 1995

110. Van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359-1367, 2001

111. Yusuf S, Mehta SR, Diaz R, et al: Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: The CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction. Am Heart J 148:1068-1078, 2004

112. Mehta SR, Yusuf S, Diaz R, et al: Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial. JAMA 293:437-446, 2005

113. Van den Berghe G, Wilmer A, Hermans G, et al: Intensive insulin therapy in the medical ICU. N Engl J Med 354:449-461, 2006

114. Malmberg K, Ryden L, Wedel H, et al: Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. Eur Heart J 26:650-661, 2005

115. Nathan DM, Cleary PA, Backlund JY, et al: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653, 2005

116. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998

117. Dormandy JA, Charbonnel B, Eckland DJ, et al: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366:1279-1289, 2005

118. Kao J, Tobis J, McClelland RL, et al: Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 93:1347-1350, A1345, 2004

119. Gibler WB, Cannon CP, Blomkalns AL, et al: Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: A scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers. Circulation 111:2699-2710, 2005

120. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA: Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 41:718-724, 2003

121. Reddan DN, Szczech L, Bhapkar MV, et al: Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial Transplant 20:2105-2112, 2005

122. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137:555-562, 2002

123. Wright RS, Reeder GS, Herzog CA, et al: Acute myocardial infarction and renal dysfunction: A high-risk combination. Ann Intern Med 137:563-570, 2002

124. Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA: Survival after coronary revascularization among patients with kidney disease. Circulation 110:1890-1895, 2004

125. Reddan DN, Szczech LA, Tuttle RH, et al: Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol 14:2373-2380, 2003

126. Ix JH, Mercado N, Shlipak MG, et al: Association of chronic kidney disease with clinical outcomes after coronary revascularization: The Arterial Revascularization Therapies Study (ARTS). Am Heart J 149:512-519, 2005

127. Moussa I, Leon MB, Baim DS, et al: Impact of sirolimus-eluting stents on outcome in diabetic patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109:2273-2278, 2004

128. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, et al: Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: The diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 112:2175-2183, 2005

129. Hermiller JB, Raizner A, Cannon L, et al: Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: The TAXUS-IV trial. J Am Coll Cardiol 45:1172-1179, 2005

130. Mehilli J, Kastrati A, Schuhlen H, et al: Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110:3627-3635, 2004

131. Marso SP, Ellis SG, Tuzcu M, et al: The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. J Am Coll Cardiol 33:1269-1277, 1999

132. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993

133. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA 290:2159-2167, 2003

134. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998

135. Levin SR, Coburn JW, Abraira C, et al: Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care 23:1478-1485, 2000

136. Ohkubo Y, Kishikawa H, Araki E, et al: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995

137. Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23:B21-B29, 2000 (suppl 2)

138. Reichard P, Nilsson BY, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993

139. Brocco E, Velussi M, Cernigoi AM, et al: Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy. J Nephrol 14:461-471, 2001

140. Holman RR, Dornan TL, Mayon-White V, et al: Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients. A two-year randomised prospective study. Lancet 1:204-208, 1983

141. Viberti GC, Bilous RW, Mackintosh D, Bending JJ, Keen H: Long term correction of hyperglycaemia and progression of renal failure in insulin dependent diabetes. Br Med J 286:598-602, 1983

142. Gerich JE, Meyer C, Woerle HJ, Stumvoll M: Renal gluconeogenesis: Its importance in human glucose homeostasis. Diabetes Care 24:382-391, 2001

143. Hasslacher C, Wittmann W: [Severe hypoglycemia in diabetics with impaired renal function]. Dtsch Med Wochenschr 128:253-256, 2003

144. Muhlhauser I, Toth G, Sawicki PT, Berger M: Severe hypoglycemia in type I diabetic patients with impaired kidney function. Diabetes Care 14:344-346, 1991

145. Yu CC, Wu MS, Wu CH, et al: Predialysis glycemic control is an independent predictor of clinical outcome in type II diabetics on continuous ambulatory peritoneal dialysis. Perit Dial Int 17:262-268, 1997

146. Morioka T, Emoto M, Tabata T, et al: Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 24:909-913, 2001

147. Brocco E, Fioretto P, Mauer M, et al: Renal structure and function in non-insulin dependent diabetic patients with microalbuminuria. Kidney Int Suppl 63:S40-S44, 1997

148. Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P: Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 26:S8-S14, 2000 (suppl 4)

149. de Courten MP, Pettitt DJ, Knowler WC: Hypertension in Pima Indians: Prevalence and predictors. Public Health Rep 111:S40-S43, 1996 (suppl 2)

150. Go RC, Desmond R, Roseman JM, Bell DS, Vanichanan C, Acton RT: Prevalence and risk factors of microalbuminuria in a cohort of African-American women with gestational diabetes. Diabetes Care 24:1764-1769, 2001

151. Parving HH, Hommel E, Mathiesen E, et al: Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J 296:156-160, 1988

152. Tobe SW, McFarlane PA, Naimark DM: Microalbuminuria in diabetes mellitus. CMAJ 167:499-503, 2002

153. Wachtell K, Palmieri V, Olsen MH, et al: Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Losartan Intervention for Endpoint Reduction. Am Heart J 143:319-326, 2002

154. Chobanian AV, Bakris GL, Black HR, et al: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206-1252, 2003

155. Agardh CD, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett AH: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 10:185-192, 1996

156. Chan JC, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R: Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One year analysis. BMJ 305:981-985, 1992

157. Chan JC, Ko GT, Leung DH, et al: Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 57:590-600, 2000

158. De Cesaris R, Ranieri G, Andriani A, et al: Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with diabetes. Clin Pharmacol Ther 60:472-478, 1996

159. Laffel LM, McGill JB, Gans DJ: The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 99:497-504, 1995

160. Mathiesen ER, Hommel E, Giese J, Parving HH: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 303:81-87, 1991

161. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001

162. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 156:286-289, 1996

163. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577-581, 1993

164. Schnack C, Hoffmann W, Hopmeier P, Schernthaner G: Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Diabetologia 39:1611-1616, 1996

165. Trevisan R, Tiengo A: Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 8:876-883, 1995

166. Viberti G, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 271:275-279, 1994

167. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001

168. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993

169. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001

170. Koshy S, Bakris GL: Therapeutic approaches to achieve desired blood pressure goals: Focus on calcium channel blockers. Cardiovasc Drugs Ther 14:295-301, 2000

171. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis 34:809-817, 1999

172. Rahman M, Pressel S, Davis BR, et al: Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165:936-946, 2005

173. Bakris GL, Weir MR, Shanifar S, et al: Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL Study. Arch Intern Med 163:1555-1565, 2003

174. Standards of medical care in diabetes. Diabetes Care 28:S4-S36, 2005 (suppl 1)

175. Grundy SM, Cleeman JI, Merz CN, et al: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239, 2004

176. Snow V, Aronson MD, Hornbake ER, Mottur-Pilson C, Weiss KB: Lipid control in the management of type 2 diabetes mellitus: A clinical practice guideline from the American College of Physicians. Ann Intern Med 140:644-649, 2004

177. Vijan S, Hayward RA: Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: Background paper for the American College of Physicians. Ann Intern Med 140:650-658, 2004

178. Wright JD, Wang C-Y, Kennedy-Stephenson J, Ervin RB: Dietary intake of ten key nutrients for public health, United States: 1999-2000. Hyattsville, MD, Centers for Disease Control and Prevention, National Center for Health Statistics, 2003, pp 1-4

179. Kasiske BL, Lakatua JD, Ma JZ, Louis TA: A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 31:954-961, 1998

180. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH: The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis. Ann Intern Med 124:627-632, 1996

181. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH: Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 62:220-228, 2002

182. Azadbakht L, Shakerhosseini R, Atabak S, Jamshidian M, Mehrabi Y, Esmaill-Zadeh A: Beneficiary effect of dietary soy protein on lowering plasma levels of lipid and improving kidney function in type II diabetes with nephropathy. Eur J Clin Nutr 57:1292-1294, 2003

183. Dullaart RP, Beusekamp BJ, Meijer S, van Doormaal JJ, Sluiter WJ: Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension. Diabetes Care 16:483-492, 1993

184. Meloni C, Morosetti M, Suraci C, et al: Severe dietary protein restriction in overt diabetic nephropathy: Benefits or risks? J Ren Nutr 12:96-101, 2002

185. Pecis M, de Azevedo MJ, Gross JL: Chicken and fish diet reduces glomerular hyperfiltration in IDDM patients. Diabetes Care 17:665-672, 1994

186. Raal FJ, Kalk WJ, Lawson M, et al: Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: A 6-mo prospective study. Am J Clin Nutr 60:579-585, 1994

187. Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982

188. Gin H, Aparicio M, Potaux L, et al: Low-protein, low-phosphorus diet and tissue insulin sensitivity in insulin-dependent diabetic patients with chronic renal failure. Nephron 57:411-415, 1991

189. Hansen HP, Christensen PK, Tauber-Lassen E, Klausen A, Jensen BR, Parving HH: Low-protein diet and kidney function in insulin-dependent diabetic patients with diabetic nephropathy. Kidney Int 55:621-628, 1999

190. Hostetter TH, Meyer TW, Rennke HG, Brenner BM: Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int 30:509-517, 1986

191. Meek RL, Cooney SK, Flynn SD, et al: Amino acids induce indicators of response to injury in glomerular mesangial cells. Am J Physiol Renal Physiol 285:F79-F86, 2003

192. Tuttle KR, Bruton JL: Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes. Kidney Int 42:167-173, 1992

193. Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT, DeFronzo RA: Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 324:1626-1632, 1991

194. Tuttle KR, Johnson EC, Cooney SK, et al: Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C. Kidney Int 67:953-968, 2005

195. Tuttle KR, Puhlman ME, Cooney SK, Short RA: Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes. Am J Physiol Renal Physiol 282:F103-F112, 2002

196. Zatz R, Meyer TW, Rennke HG, Brenner BM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A 82:5963-5967, 1985

197. Knight EL, Stampfer MJ, Hankinson SE, Spiegelman D, Curhan GC: The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency. Ann Intern Med 138:460-467, 2003

198. Wrone EM, Carnethon MR, Palaniappan L, Fortmann SP: Association of dietary protein intake and microalbuminuria in healthy adults: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41:580-587, 2003

199. Sacks FM, Svetkey LP, Vollmer WM, et al: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 344:3-10, 2001

200. Appel LJ, Sacks FM, Carey VJ, et al: Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: Results of the OmniHeart randomized trial. JAMA 294:2455-2464, 2005

201. He J, Gu D, Wu X, et al: Effect of soybean protein on blood pressure: A randomized, controlled trial. Ann Intern Med 143:1-9, 2005

202. Jibani MM, Bloodworth LL, Foden E, Griffiths KD, Galpin OP: Predominantly vegetarian diet in patients with incipient and early clinical diabetic nephropathy: Effects on albumin excretion rate and nutritional status. Diabet Med 8:949-953, 1991

203. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 134:370-379, 2001

204. Ahmad J, Shafique S, Abidi SM, Parwez I: Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects. Diabetes Res Clin Pract 60:131-138, 2003

205. Cordonnier DJ, Pinel N, Barro C, et al: Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. J Am Soc Nephrol 10:1253-1263, 1999

206. Ravid M, Savin H, Jutrin I, Bental T, Lang R, Lishner M: Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Int Suppl 45:S161-S164, 1994

207. Sano T, Hotta N, Kawamura T, et al: Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: Results of a 4-year, prospective, randomized study. Diabet Med 13:120-124, 1996

208. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH: Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 319:24-25, 1999

209. Andersen S, Brochner-Mortensen J, Parving HH: Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 26:3296-3302, 2003

210. Atkins RC, Briganti EM, Lewis JB, et al: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 45:281-287, 2005

211. de Zeeuw D, Remuzzi G, Parving HH, et al: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110:921-927, 2004

212. de Zeeuw D, Remuzzi G, Parving HH, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 65:2309-2320, 2004

213. Calvo G, de Andres-Trelles F: Albuminuria as a surrogate marker for drug development: A European Regulatory perspective. Kidney Int Suppl 92:S126-S127, 2004

214. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288:1723-1727, 2002

215. Kidney Early Evaluation Program. Am J Kidney Dis 45:S1-S135, 2005 (suppl 2)

216. Hall JE, Henegar JR, Dwyer TM, et al: Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther 11:41-54, 2004

217. Hall JE, Jones DW, Kuo JJ, da Silva A, Tallam LS, Liu J: Impact of the obesity epidemic on hypertension and renal disease. Curr Hypertens Rep 5:386-392, 2003

218. Iseki K: Factors influencing the development of end-stage renal disease. Clin Exp Nephrol 9:5-14, 2005

219. Saxena A, Chopra R: Renal risks of an emerging “epidemic” of obesity: The role of adipocyte-derived factors. Dial Transplant 33:11-21, 2004

220. Soto FC, Higa-Sansone G, Copley JB, et al: Renal failure, glomerulonephritis and morbid obesity: Improvement after rapid weight loss following laparoscopic gastric bypass. Obes Surg 15:137-140, 2005

221. Wiggins KJ, Johnson DW: The influence of obesity on the development and survival outcomes of chronic kidney disease. Adv Chronic Kidney Dis 12:49-55, 2005

222. Mogensen CE, Chachati A, Christensen CK, et al: Microalbuminuria: An early marker of renal involvement in diabetes. Uremia Invest 9:85-95, 1985

223. Mathiesen ER, Ronn B, Storm B, Foght H, Deckert T: The natural course of microalbuminuria in insulin-dependent diabetes: A 10-year prospective study. Diabet Med 12:482-487, 1995

224. Caramori ML, Fioretto P, Mauer M: The need for early predictors of diabetic nephropathy risk: Is albumin excretion rate sufficient? Diabetes 49:1399-1408, 2000

225. Forsblom CM, Groop PH, Ekstrand A, Groop LC: Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration. BMJ 305:1051-1053, 1992

226. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS: Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348:2285-2293, 2003

227. Araki S, Haneda M, Sugimoto T, et al: Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 54:2983-2987, 2005

228. Caramori ML, Kim Y, Huang C, et al: Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. Diabetes 51:506-513, 2002

229. Fioretto P, Steffes MW, Mauer M: Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 43:1358-1364, 1994

230. Fioretto P, Mauer M, Carraro A, et al: Renal structural changes in non-insulin-dependent diabetes mellitus. Am J Hypertens 10:184S-188S, 1997 (suppl 1)

231. Krolewski M, Eggers PW, Warram JH: Magnitude of end-stage renal disease in IDDM: A 35 year follow-up study. Kidney Int 50:2041-2046, 1996

232. Microalbuminuria Collaborative Study Group: Risk factors for development of microalbuminuria in insulin dependent diabetic patients: A cohort study. United Kingdom. BMJ 306:1235-1239, 1993

233. Messent JW, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC: Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: A twenty-three year follow-up study. Kidney Int 41:836-839, 1992

234. MacLeod JM, Lutale J, Marshall SM: Albumin excretion and vascular deaths in NIDDM. Diabetologia 38:610-616, 1995

235. Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 2:530-533, 1988

236. Microvascular and acute complications in IDDM patients: The EURODIAB IDDM Complications Study. Diabetologia 37:278-285, 1994

237. Lloyd CE, Stephenson J, Fuller JH, Orchard TJ: A comparison of renal disease across two continents; The epidemiology of diabetes complications study and the EURODIAB IDDM Complications Study. Diabetes Care 19:219-225, 1996

238. Marshall SM, Alberti KG: Comparison of the prevalence and associated features of abnormal albumin excretion in insulin-dependent and non-insulin-dependent diabetes. Q J Med 70:61-71, 1989

239. Collins VR, Dowse GK, Finch CF, Zimmet PZ, Linnane AW: Prevalence and risk factors for micro- and macroalbuminuria in diabetic subjects and entire population of Nauru. Diabetes 38:1602-1610, 1989

240. Nelson RG, Kunzelman CL, Pettitt DJ, Saad MF, Bennett PH, Knowler WC: Albuminuria in type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in Pima Indians. Diabetologia 32:870-876, 1989

241. Simmons D, Shaw LM, Scott DJ, Kenealy T, Scragg RK: Diabetic nephropathy and microalbuminuria in the community. The South Auckland Diabetes Survey. Diabetes Care 17:1404-1410, 1994

242. Warram JH, Gearin G, Laffel L, Krolewski AS: Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 7:930-937, 1996

243. Poggio ED, Wang X, Greene T, Van Lente F, Hall PM: Performance of the Modification of Diet in Renal Disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 16:459-466, 2005

244. Ibrahim H, Mondress M, Tello A, Fan Y, Koopmeiners J, Thomas W: An alternative formula to the Cockcroft-Gault and the Modification of Diet in Renal Diseases formulas in predicting GFR in individuals with type 1 diabetes. J Am Soc Nephrol 16:1051-1060, 2005

245. Caramori ML, Fioretto P, Mauer M: Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: An indicator of more advanced glomerular lesions. Diabetes 52:1036-1040, 2003

246. Lane PH, Steffes MW, Mauer SM: Glomerular structure in IDDM women with low glomerular filtration rate and normal urinary albumin excretion. Diabetes 41:581-586, 1992

247. Brito PL, Fioretto P, Drummond K, et al: Proximal tubular basement membrane width in insulin-dependent diabetes mellitus. Kidney Int 53:754-761, 1998

248. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 74:1143-1155, 1984

249. Hovind P, Rossing P, Tarnow L, Toft H, Parving J, Parving HH: Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care 24:1972-1977, 2001

250. Viberti GC, Bilous RW, Mackintosh D, Keen H: Monitoring glomerular function in diabetic nephropathy. A prospective study. Am J Med 74:256-264, 1983

251. Parving HH, Gall MA, Skott P, et al: Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 41:758-762, 1992

252. Nosadini R, Velussi M, Brocco E, et al: Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 49:476-484, 2000

253. Amoah E, Glickman JL, Malchoff CD, Sturgill BC, Kaiser DL, Bolton WK: Clinical identification of nondiabetic renal disease in diabetic patients with type I and type II disease presenting with renal dysfunction. Am J Nephrol 8:204-211, 1988

254. Christensen PK, Gall MA, Parving HH: Course of glomerular filtration rate in albuminuric type 2 diabetic patients with or without diabetic glomerulopathy. Diabetes Care 23:B14-B20, 2000 (suppl 2)

255. Fioretto P, Mauer M, Brocco E, et al: Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39:1569-1576, 1996

256. John GT, Date A, Korula A, Jeyaseelan L, Shastry JC, Jacob CK: Nondiabetic renal disease in noninsulin-dependent diabetics in a south Indian hospital. Nephron 67:441-443, 1994

257. Kleinknecht D, Bennis D, Altman JJ: Increased prevalence of non-diabetic renal pathology in type II diabetes mellitus. Nephrol Dial Transplant 7:1258-1259, 1992

258. Mak SK, Gwi E, Chan KW, et al: Clinical predictors of non-diabetic renal disease in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant 12:2588-2591, 1997

259. Olsen S, Mogensen CE: How often is NIDDM complicated with non-diabetic renal disease? An analysis of renal biopsies and the literature. Diabetologia 39:1638-1645, 1996

260. Richards NT, Greaves I, Lee SJ, Howie AJ, Adu D, Michael J: Increased prevalence of renal biopsy findings other than diabetic glomerulopathy in type II diabetes mellitus. Nephrol Dial Transplant 7:397-399, 1992

261. Serra A, Romero R, Bayes B, Lopez D, Bonet J: Is there a need for changes in renal biopsy criteria in proteinuria in type 2 diabetes? Diabetes Res Clin Pract 58:149-153, 2002

262. Wong TY, Choi PC, Szeto CC, et al: Renal outcome in type 2 diabetic patients with or without coexisting nondiabetic nephropathies. Diabetes Care 25:900-905, 2002

263. Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N: Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: The EURODIAB Prospective Complications Study. Diabetologia 47:1020-1028, 2004

264. Hovind P, Tarnow L, Parving HH: Remission and regression of diabetic nephropathy. Curr Hypertens Rep 6:377-382, 2004

265. Bognetti E, Calori G, Meschi F, Macellaro P, Bonfanti R, Chiumello G: Prevalence and correlations of early microvascular complications in young type I diabetic patients: Role of puberty. J Pediatr Endocrinol Metab 10:587-592, 1997

266. Holl RW, Grabert M, Thon A, Heinze E: Urinary excretion of albumin in adolescents with type 1 diabetes: Persistent versus intermittent microalbuminuria and relationship to duration of diabetes, sex, and metabolic control. Diabetes Care 22:1555-1560, 1999

267. Holl RW, Pavlovic M, Heinze E, Thon A: Circadian blood pressure during the early course of type 1 diabetes. Analysis of 1,011 ambulatory blood pressure recordings in 354 adolescents and young adults. Diabetes Care 22:1151-1157, 1999

268. Kostraba JN, Dorman JS, Orchard TJ, et al: Contribution of diabetes duration before puberty to development of microvascular complications in IDDM subjects. Diabetes Care 12:686-693, 1989

269. Olsen BS, Sjolie AK, Hougaard P, et al: The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. J Diabetes Complications 18:160-164, 2004

270. Pavlovic M, Holl RW, Haeberle U, et al: Angiotensin I converting enzyme and angiotensinogen gene polymorphisms related to 24-h blood pressure in paediatric type I diabetes mellitus. Eur J Pediatr 158:18-23, 1999

271. Drummond K, Mauer M: The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 51:1580-1587, 2002

272. Nelson RG, Newman JM, Knowler WC, et al: Incidence of end-stage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia 31:730-736, 1988

273. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G: Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 27:195-200, 2004

274. Eiro M, Katoh T, Watanabe T: Risk factors for bleeding complications in percutaneous renal biopsy. Clin Exp Nephrol 9:40-45, 2005

275. Whittier WL, Korbet SM: Timing of complications in percutaneous renal biopsy. J Am Soc Nephrol 15:142-147, 2004

276. Korbet SM: Percutaneous renal biopsy. Semin Nephrol 22:254-267, 2002

277. Whittier WL, Korbet SM: Renal biopsy: update. Curr Opin Nephrol Hypertens 13:661-665, 2004

278. Manno C, Strippoli GF, Arnesano L, et al: Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney Int 66:1570-1577, 2004

279. Mattix H, Singh AK: Is the bleeding time predictive of bleeding prior to a percutaneous renal biopsy? Curr Opin Nephrol Hypertens 8:715-718, 1999

280. Mendelssohn DC, Cole EH: Outcomes of percutaneous kidney biopsy, including those of solitary native kidneys. Am J Kidney Dis 26:580-585, 1995

281. Cahill RA, McGreal GT, Crowe BH, et al: Duration of increased bleeding tendency after cessation of aspirin therapy. J Am Coll Surg 200:564-573; quiz, A559-A561, 2005

282. Donovan KL, Thomas DM, Wheeler DC, Macdougall IC, Williams JD: Experience with a new method for percutaneous renal biopsy. Nephrol Dial Transplant 6:731-733, 1991

283. Kearon C, Hirsh J: Management of anticoagulation before and after elective surgery. N Engl J Med 336:1506-1511, 1997

284. Nass K, O'Neill WC: Bedside renal biopsy: Ultrasound guidance by the nephrologist. Am J Kidney Dis 34:955-959, 1999

285. Peterson P, Hayes TE, Arkin CF, et al: The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 133:134-139, 1998

286. Stiles KP, Hill C, LeBrun CJ, Reinmuth B, Yuan CM, Abbott KC: The impact of bleeding times on major complication rates after percutaneous real-time ultrasound-guided renal biopsies. J Nephrol 14:275-279, 2001

287. Zeigler ZR, Megaludis A, Fraley DS: Desmopressin (d-DAVP) effects on platelet rheology and von Willebrand factor activities in uremia. Am J Hematol 39:90-95, 1992

288. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ: Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 348:491-499, 2003

289. Barrett BJ, Parfrey PS, Vavasour HM, et al: Contrast nephropathy in patients with impaired renal function: High versus low osmolar media. Kidney Int 41:1274-1279, 1992

290. Rudnick MR, Goldfarb S, Wexler L, et al: Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial. The Iohexol Cooperative Study. Kidney Int 47:254-261, 1995

291. Parfrey PS, Griffiths SM, Barrett BJ, et al: Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 320:143-149, 1989

292. Rihal CS, Textor SC, Grill DE, et al: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105:2259-2264, 2002

293. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW: Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 103:368-375, 1997

294. Nolin TD, Himmelfarb J, Matzke GR: Drug-induced kidney disease, in DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds): Pharmacotherapy: A Physiological Approach. New York, NY, McGraw-Hill, 2005, pp 871-890

295. Merten GJ, Burgess WP, Gray LV, et al: Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 291:2328-2334, 2004

296. Sadeghi HM, Stone GW, Grines CL, et al: Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 108:2769-2775, 2003

297. Manske CL, Sprafka JM, Strony JT, Wang Y: Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 89:615-620, 1990

298. Mueller C, Buerkle G, Buettner HJ, et al: Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 162:329-336, 2002

299. Thomsen HS: Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol 181:1463-1471, 2003

300. Marenzi G, Marana I, Lauri G, et al: The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 349:1333-1340, 2003

301. Pannu N, Manns B, Lee H, Tonelli M: Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 65:1366-1374, 2004

302. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ: Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: A meta-analysis of randomized, controlled trials. Am J Kidney Dis 43:1-9, 2004

303. Barrett BJ, Parfrey PS: Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 354:379-386, 2006

304. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH: Microalbuminuria in type 1 diabetes: Rates, risk factors and glycemic threshold. Kidney Int 60:219-227, 2001

305. Scott LJ, Warram JH, Hanna LS, Laffel LM, Ryan L, Krolewski AS: A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 50:2842-2849, 2001

306. Hovind P, Tarnow L, Rossing P, et al: Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: Inception cohort study. BMJ 328:1105, 2004

307. Agardh CD, Agardh E, Torffvit O: The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: A 5 year follow-up study of 442 adult patients in routine care. Diabetes Res Clin Pract 35:113-121, 1997

308. Osterby R, Hartmann A, Bangstad HJ: Structural changes in renal arterioles in type I diabetic patients. Diabetologia 45:542-549, 2002

309. Torffvit O, Agardh CD: The predictive value of albuminuria for cardiovascular and renal disease. A 5-year follow-up study of 476 patients with type I diabetes mellitus. J Diabetes Complications 7:49-56, 1993

310. Schultz CJ, Neil HA, Dalton RN, Dunger DB: Oxforn Regional Prospective Study G: Risk of nephropathy can be detected before the onset of microalbuminuria during the early years after diagnosis of type 1 diabetes. Diabetes Care 23:1811-1815, 2000

311. Rachmani R, Levi Z, Lidar M, Slavachevski I, HalfOnn E, Ravid M: Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: Lessons from an 8-year follow-up study of 599 patients. Diabetes Res Clin Pract 49:187-194, 2000

312. Nelson RG, Bennett PH, Beck GJ, et al: Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 335:1636-1642, 1996

313. Nelson RG, Knowler WC, McCance DR, et al: Determinants of end-stage renal disease in Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus and proteinuria. Diabetologia 36:1087-1093, 1993

314. Sosenko JM, Hu D, Welty T, Howard BV, Lee E, Robbins DC: Albuminuria in recent-onset type 2 diabetes: The Strong Heart Study. Diabetes Care 25:1078-1084, 2002

315. Chan JC, Cheung CK, Cheung MY, Swaminathan R, Critchley JA, Cockram CS: Abnormal albuminuria as a predictor of mortality and renal impairment in Chinese patients with NIDDM. Diabetes Care 18:1013-1016, 1995

316. Torffvit O, Agardh CD: The impact of metabolic and blood pressure control on incidence and progression of nephropathy. A 10-year study of 385 type 2 diabetic patients. J Diabetes Complications 15:307-313, 2001

317. John L, Rao PS, Kanagasabapathy AS: Rate of progression of albuminuria in type II diabetes. Five-year prospective study from south India. Diabetes Care 17:888-890, 1994

318. Bruno G, Biggeri A, Merletti F, et al: Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes: A 10-year prospective study. Diabetes Care 26:2353-2358, 2003

319. Lane PH, Steffes MW, Fioretto P, Mauer SM: Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int 43:661-667, 1993

320. Harris RD, Steffes MW, Bilous RW, Sutherland DE, Mauer SM: Global glomerular sclerosis and glomerular arteriolar hyalinosis in insulin dependent diabetes. Kidney Int 40:107-114, 1991

321. Ellis EN, Steffes MW, Goetz FC, Sutherland DE, Mauer SM: Glomerular filtration surface in type I diabetes mellitus. Kidney Int 29:889-894, 1986

322. Fioretto P, Steffes MW, Sutherland DE, Mauer M: Sequential renal biopsies in insulin-dependent diabetic patients: Structural factors associated with clinical progression. Kidney Int 48:1929-1935, 1995

323. Najafian B, Kim Y, Crosson JT, Mauer M: Atubular glomeruli and glomerulotubular junction abnormalities in diabetic nephropathy. J Am Soc Nephrol 14:908-917, 2003

324. Bangstad HJ, Osterby R, DahlJorgensen K, et al: Early glomerulopathy is present in young, type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 36:523-529, 1993

325. Ellis EN, Warady BA, Wood EG, et al: Renal structural-functional relationships in early diabetes mellitus. Pediatr Nephrol 11:584-591, 1997

326. Bjorn SF, Bangstad HJ, Hanssen KF, et al: Glomerular epithelial foot processes and filtration slits in IDDM patients. Diabetologia 38:1197-1204, 1995

327. White KE, Bilous RW: Type 2 diabetic patients with nephropathy show structural